Format

Send to

Choose Destination
J Allergy Clin Immunol. 2018 Jan;141(1):279-292. doi: 10.1016/j.jaci.2017.01.045. Epub 2017 Apr 20.

Vitamin D downregulates the IL-23 receptor pathway in human mucosal group 3 innate lymphoid cells.

Author information

1
Center for Infectious Medicine, Department of Medicine, Huddinge, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden; Institute of Experimental and Clinical Pharmacology, Medical University of Graz, Graz, Austria.
2
Science for Life Laboratory, Department of Medicine, Stockholm, Sweden.
3
Center for Infectious Medicine, Department of Medicine, Huddinge, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.
4
Center for Digestive Diseases, Department of Medicine, Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.
5
Department of Molecular Medicine and Surgery, Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.
6
Department of Otorhinolaryngology, Department of Clinical Science, Intervention and Technology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.
7
Unit for Inflammation, Gastroenterology and Rheumatology, Department of Medicine, Huddinge, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.
8
Center for Infectious Medicine, Department of Medicine, Huddinge, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden; Clinical Microbiology, Department of Laboratory Medicine, Huddinge, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.
9
Center for Infectious Medicine, Department of Medicine, Huddinge, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden; Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden. Electronic address: jenny.mjosberg@ki.se.

Abstract

BACKGROUND:

Vitamin D deficiency is a risk factor for inflammatory bowel disease (IBD). The IL-23-driven tissue-resident group 3 innate lymphoid cells (ILC3s) play essential roles in intestinal immunity, and targeting IL-23/12 is a promising approach in IBD therapy.

OBJECTIVE:

We set out to define the role of 1α,25-dihydroxy vitamin D3 (1,25D) in regulating functional responses of human mucosal ILC3s to IL-23 plus IL-1β stimulation.

METHODS:

Transcriptomes of sorted tonsillar ILC3s were assessed by using microarray analysis. ILC3 cytokine production, proliferation, and differentiation were determined by means of flow cytometry, ELISA, and multiplex immunoassay. Intestinal cell suspensions and ILC3s sorted from gut biopsy specimens of patients with IBD were also analyzed along with plasma 25-hydroxy vitamin D3 (25D) detection.

RESULTS:

ILC3s stimulated with IL-23 plus IL-1β upregulated the vitamin D receptor and responded to 1,25D with downregulation of the IL-23 receptor pathway. Consequently, 1,25D suppressed IL-22, IL-17F, and GM-CSF production from tonsillar and gut ILC3s. In parallel, 1,25D upregulated genes linked to the IL-1β signaling pathway, as well as the IL-1β-inducible cytokines IL-6, IL-8, and macrophage inflammatory protein 1α/β. The 1,25D-triggered skewing in ILC3 function was not accompanied or caused by changes in viability, proliferation, or phenotype. Finally, we confirmed low 25D plasma levels in patients with IBD with active inflammation.

CONCLUSION:

In light of the beneficial targeting of IL-23/12 in patients with IBD, 1,25D appears as an interesting therapeutic agent that inhibits the IL-23 receptor pathway, providing a novel mechanism for how ILC3s could be manipulated to regulate intestinal inflammation.

KEYWORDS:

IL-22; Innate lymphoid cells; inflammatory bowel diseases; vitamin D receptor

PMID:
28433688
DOI:
10.1016/j.jaci.2017.01.045

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center